Denali Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 507

Employees

  • Stock Symbol
  • DNLI

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $18.45
  • (As of Friday Closing)

Denali Therapeutics General Information

Description

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 161 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 161 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Denali Therapeutics Stock Performance

As of 20-Nov-2026, Denali Therapeutics’s stock price is $18.45. Its current market cap is $2.96B with 160M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$18.45 $18.20 $15.34 - $27.30 $2.96B 160M 1.66M -$1.72

Denali Therapeutics Financials Summary

As of 30-Sep-2026, Denali Therapeutics has a trailing 12-month revenue of $21.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,625,782 1,774,375 2,149,081 1,910,349
Revenue 21,382 0 0 330,531
EBITDA (321,496) (540,530) (478,349) (179,973)
Net Income (314,423) (512,540) (422,773) (145,224)
Total Assets 1,256,035 1,144,854 1,374,180 1,153,917
Total Debt 29,792 36,756 48,707 52,241
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Denali Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat
Biotechnology
South San Francisco, CA
507 As of 2026

South San Francisco, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Denali Therapeutics Competitors (68)

One of Denali Therapeutics’s 68 competitors is Alector, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alector Formerly VC-backed South San Francisco, CA
Beam Therapeutics Formerly VC-backed Cambridge, MA
Design Therapeutics Formerly VC-backed Carlsbad, CA
Avidity Biosciences Formerly VC-backed San Diego, CA
Lisata Therapeutics Corporation Basking Ridge, NJ
You’re viewing 5 of 68 competitors. Get the full list »

Denali Therapeutics Patents

Denali Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026169916-A1 Dosing regimen for a treatment of hunter syndrome Pending 05-Feb-2025
WO-2026136804-A1 Compositions and methods for modulating synuclein expression Pending 20-Dec-2024
WO-2026060081-A1 Anti-amyloid beta antibodies and methods of use Pending 12-Sep-2024
WO-2026006173-A1 Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof Pending 24-Jun-2024
AU-2025208177-A1 Chemically modified oligonucleotides and conjugates and methods thereof Pending 08-Jan-2024 C07K19/00
To view Denali Therapeutics’s complete patent history, request access »

Denali Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Denali Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Investments & Acquisitions (3)

Denali Therapeutics’s most recent deal was a Merger/Acquisition with F-star Gamma for . The deal was made on 30-May-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
F-star Gamma 30-May-2018 Merger/Acquisition Biotechnology
Incro Pharmaceuticals 25-Aug-2016 Merger/Acquisition Biotechnology
F-star Gamma 05-Jun-2016 Secondary Transaction - Private Biotechnology
To view Denali Therapeutics’s complete investments and acquisitions history, request access »

Denali Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.23 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Denali Therapeutics’s complete esg history, request access »

Denali Therapeutics FAQs

  • When was Denali Therapeutics founded?

    Denali Therapeutics was founded in 2015.

  • Where is Denali Therapeutics headquartered?

    Denali Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Denali Therapeutics?

    Denali Therapeutics has 507 total employees.

  • What industry is Denali Therapeutics in?

    Denali Therapeutics’s primary industry is Biotechnology.

  • Is Denali Therapeutics a private or public company?

    Denali Therapeutics is a Public company.

  • What is Denali Therapeutics’s stock symbol?

    The ticker symbol for Denali Therapeutics is DNLI.

  • What is the current stock price of Denali Therapeutics?

    As of 20-Nov-2026 the stock price of Denali Therapeutics is $18.45.

  • What is the current market cap of Denali Therapeutics?

    The current market capitalization of Denali Therapeutics is $2.96B.

  • What is Denali Therapeutics’s current revenue?

    The trailing twelve month revenue for Denali Therapeutics is $21.4M.

  • Who are Denali Therapeutics’s competitors?

    Alector, Beam Therapeutics, Design Therapeutics, Avidity Biosciences, and Lisata Therapeutics are some of the 68 competitors of Denali Therapeutics.

  • What is Denali Therapeutics’s annual earnings per share (EPS)?

    Denali Therapeutics’s EPS for 12 months was -$1.72.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process